

Analyst & Investor Conference Call
2019 Q1 Financial Results

epigenomics

Greg Hamilton, Chief Executive Officer

May 8, 2019



Safe harbor statement

This communication contains certain forward-looking statements, including, without limitation, statements containing the words “expects”, “future”, “potential” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Q1 2019 Operational highlights

- CMS accepted Epi proColon National Coverage Determination (NCD) application



- Microsimulation model manuscript submitted for publication

- Reintroduction of the bi-partisan "Donald Payne Sr. Colorectal Cancer Detection Act" (HR 1765) to the U.S. House of Representatives

Medicare National Coverage Determination Process



Example Timeline

Jul 1, 2019 — Dec 31, 2019 — Apr 1, 2020 — Go-live*

* Assumes positive coverage decision

Key Reimbursement Coverage Milestones

Legislation

- [x] "Blood Test" Coverage Urged in 2019 Health and Human Services Appropriations Bill
- [x] Epi's work with Congressional Budget Office (CBO) complete
- [x] Bi-partisan House Bill H.R. 1765 was re-introduced
- [ ] Bi-partisan Senate Bill re-introduced (expected shortly)
- [ ] "Blood Test" Bill Move to Vote or Incorporated into Larger Bill for Vote

National Coverage Decision (NCD)

- [x] FDA-Approval
- [x] CMS sets final Price => $192
- [x] NCD application Accepted
- [ ] Proposed Decision Memo
- [ ] Final Decision Memo

Q1 2019 - Key financials

EURm	Q1-2019	Q1-2018	Variance
Revenue	0.3	0.3	0.0
Adj. EBITDA*	(3.0)	(3.2)	0.2
Net result	(3.0)	(3.2)	0.2
Cash consumption	4.3	2.4	1.9

*EBITDA before share-based payment expenses

- Higher product sales (+198%) for Epi proColon, no licensing revenue in 2019
- Adjusted EBITDA and Net Result improved compared to previous year
- Cash consumption increased due to higher operating cash outflow partly due to previous year liabilities

Liquid assets

EURm	Mar 31, 2019	Dec 31, 2018
Liquid assets*	12.9	17.1

*cash and cash equivalents incl. marketable securities

- Liquidity consistent with guidance
- Current funds sufficient to continue business operations well into 2020

HCC BloodTest™ for Liver Cancer Detection

Global Liver Cancer Market: > $3.5 Billion

- In China, HCC is the second most frequent cancer and the leading cause of cancer-related deaths
  - A total of 466,000 new cases of HCC in 2015 and an estimated 422,100 deaths
- In the US over 40,000 people will be diagnosed with HCC in 2018
  - Close to an estimated 3 million people may suffer from Cirrhosis in the US
- Liver cancer is responsible for around 47,000 deaths per year in the EU
  - An estimated 3 million people may suffer from Cirrhosis in the EU, including those who are asymptomatic

Next Steps:

- Cross-sectional U.S. Study Enrolling
- Pre-submission Meeting with FDA
- Initiation of Longitudinal Prospective Clinical Trial in U.S.

Financial outlook 2019 - Unchanged

Within range of EUR 3.0m to 6.0m

Within range of EUR -11.5m to -14.0m

In line with EBITDA* guidance

*EBITDA before share-based payment expenses

2019 Goals

Operational

- Coverage
- Test Volume Growth
- Initiate U.S. FDA Liver Cancer Trial

Financial

- Secure 2020 Growth Capital Post Reimbursement



Analyst & Investor Conference Call

2019 Q1 Financial Results

Q&A-Session